<DOC>
	<DOC>NCT01099176</DOC>
	<brief_summary>The study is planned to show whether monotherapies or combined hypolipemic therapy influence the fasting plasma glucose, serum adipokines (leptin, adiponectin, resistin) and proinflammatory cytokines (interleukin-6, TNF alpha) during 30 and 90 day course.</brief_summary>
	<brief_title>Effects of Hypolipemic Treatment on Adipokines</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Age (3564yr) Primary hyperlipidemia (Total cholesterol &gt;200mg/dl, Triglycerides &gt;150mg/dl) Impaired fasting glycemia (glycemia 100125mg/dl) For women: Menopause (&gt;12 months) Post hysterectomy Mechanical contraception Obtained informed consent Secondary hyperlipidemia Morbid obesity (BMI&gt;40kg/m2) Alcohol or drug abuse Acute or chronic inflammation Congestive Heart Failure (NYHA III or IV) Unstable Ischaemic Heart Disease Moderate or severe hypertension Cancer in less than 5 years Chronic kidney disease (stage IIIV) Liver failure Diabetes Oral contraception Not compliant patient Laboratory results: alanine transferase (&gt;3xULN) creatine kinase (&gt;5xULN) haemoglobin (&lt;10/dl) PLT (&lt;100G/l) WBC (&lt;3,5G/l or &gt;10G/l)</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>hyperlipidemia</keyword>
	<keyword>impaired fasting glycemia</keyword>
	<keyword>adipokines</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>fenofibrate</keyword>
</DOC>